Cite
MLA Citation
A. Armstrong et al.. “Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.” Current medical research and opinion, vol. 33, 2017, pp. 1133–1139. http://access.bl.uk/ark:/81055/vdc_100046346071.0x00004c